Results

1–4 of 4 results for EYP-1901

Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
Rishi P. Singh, MD
Updates from the Field
2022